| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Over the last 12 months, insiders at IN8bio, Inc. have bought $0 and sold $0 worth of IN8bio, Inc. stock.
On average, over the past 5 years, insiders at IN8bio, Inc. have bought $1.44M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,500 shares for transaction amount of $2,375 was made by Graff Jeremy R. (director) on 2023‑09‑13.
| 2023-09-13 | Graff Jeremy R. | director | 2,500 0.0077% | $0.95 | $2,375 | +8.97% | ||
| 2023-08-25 | McCall Patrick | Chief Financial Officer | 1,000 0.0032% | $1.03 | $1,030 | +0.49% | ||
| 2023-08-24 | Ho William Tai-Wei | President and CEO | 23,800 0.0719% | $1.05 | $24,990 | +0.98% | ||
| 2022-12-12 | Kreis Leslie W. | director | 75,001 0.359% | $2.48 | $185,912 | -45.34% | ||
| 2022-12-12 | Fletcher Aaron G.L. | director | 75,001 0.359% | $2.48 | $185,912 | -45.34% | ||
| 2022-09-28 | Kreis Leslie W. | 25,000 0.1111% | $2.02 | $50,535 | -18.57% | |||
| 2022-09-28 | Fletcher Aaron G.L. | 25,000 0.1111% | $2.02 | $50,535 | -18.57% | |||
| 2022-08-26 | Cavu Advisors, LLC | 31,805 0.1513% | $2.02 | $64,232 | -5.36% | |||
| 2022-08-17 | Cavu Advisors, LLC | 38,035 0.1712% | $1.93 | $73,408 | -5.56% | |||
| 2022-08-17 | BIOS Advisors GP, LLC | 38,035 0.1712% | $1.93 | $73,408 | -5.56% | |||
| 2022-08-16 | Transcend Partners Opportunity Fund LLC | 789,473 3.713% | $1.90 | $1.5M | +0.53% | |||
| 2022-08-16 | Ho William Tai-Wei | President, CEO and CFO | 26,315 0.1238% | $1.90 | $49,999 | +0.53% | ||
| 2022-08-16 | Cavu Advisors, LLC | 206,575 0.9715% | $1.90 | $392,493 | +0.53% | |||
| 2022-08-16 | BIOS Advisors GP, LLC | 206,575 0.9715% | $1.90 | $392,493 | +0.53% | |||
| 2022-08-16 | Brandt Peter C. | 105,263 0.4951% | $1.90 | $200,000 | +0.53% | |||
| 2022-08-16 | Lamb Lawrence | EVP and CSO | 526 0.0025% | $1.90 | $999 | +0.53% | ||
| 2022-08-16 | Roemer Alan S. | 26,315 0.1238% | $1.90 | $49,999 | +0.53% | |||
| 2022-08-16 | Greenwood Luba | 526 0.0025% | $1.90 | $999 | +0.53% | |||
| 2022-08-16 | Rochlin Kate | Chief Operating Officer | 5,263 0.0248% | $1.90 | $10,000 | +0.53% | ||
| 2022-08-16 | McCall Patrick | Chief Financial Officer | 5,263 0.0248% | $1.90 | $10,000 | +0.53% |
| Transcend Partners Opportunity Fund LLC | 4111958 88.7097% | $7.07M | 1 | 0 | ||
| Fletcher Aaron G.L. | director | 3727597 80.4176% | $6.41M | 2 | 0 | |
| Kreis Leslie W. | director | 3727597 80.4176% | $6.41M | 2 | 0 | |
| Cavu Advisors, LLC | 3651528 78.7765% | $6.28M | 3 | 0 | ||
| BIOS Advisors GP, LLC | 3612569 77.9361% | $6.21M | 2 | 0 | ||
| FAIRBAIRN EMILY | 3322485 71.6779% | $5.71M | 1 | 0 | ||
| Ho William Tai-Wei | President and CEO | 2339545 50.4724% | $4.02M | 2 | 0 | +0.98% |
| Brandt Peter C. | 182473 3.9366% | $313,853.56 | 1 | 0 | ||
| Lamb Lawrence | EVP and CSO | 99730 2.1515% | $171,535.60 | 1 | 0 | |
| Roemer Alan S. | 55989 1.2079% | $96,301.08 | 1 | 0 | ||
| Greenwood Luba | 7826 0.1688% | $13,460.72 | 1 | 0 | ||
| McCall Patrick | Chief Financial Officer | 6263 0.1351% | $10,772.36 | 2 | 0 | +0.49% |
| Rochlin Kate | Chief Operating Officer | 5263 0.1135% | $9,052.36 | 1 | 0 | |
| Goswami Trishna | Chief Medical Officer | 2631 0.0568% | $4,525.32 | 1 | 0 | |
| Graff Jeremy R. | director | 2500 0.0539% | $4,300.00 | 1 | 0 | +8.97% |
$1,029,337 | 36 | -28.38% | $7.83M | |
$63,749,694 | 24 | -12.24% | $8.06M | |
$37,200,153 | 21 | -47.67% | $8.25M | |
$1,039,491 | 21 | -11.76% | $6.84M | |
$79,536,861 | 15 | -6.81% | $9.83M | |
$405,510 | 11 | -46.23% | $6.41M | |
$188,726 | 11 | -28.87% | $8.17M | |
$20,759,738 | 11 | -44.68% | $9.92M | |
$11,777,042 | 10 | -11.94% | $9.33M | |
$120,379 | 10 | -24.48% | $7.28M | |
$241,042 | 9 | -11.02% | $8.81M | |
$90,087 | 9 | 20.06% | $9.68M | |
$211,895 | 8 | -39.70% | $7.03M | |
$159,974 | 7 | -18.60% | $6.45M | |
$149,996 | 5 | 16.26% | $8.74M | |
$1,184,658 | 4 | -22.17% | $7.38M | |
$1,057,000 | 3 | 5.27% | $6.54M | |
IN8bio, Inc. (INAB) | $28,395 | 3 | 3.48% | $7.97M |
$31,190 | 2 | -14.18% | $6.9M |
| Increased Positions | 13 | +59.09% | 2M | +243.66% |
| Decreased Positions | 10 | -45.45% | 164,953 | -16.83% |
| New Positions | 6 | New | 776,507 | New |
| Sold Out Positions | 4 | Sold Out | 69,259 | Sold Out |
| Total Postitions | 25 | +13.64% | 3M | +226.83% |
| Bios Capital Management, Lp | $705.00 | 5.73% | 286,664 | 0 | 0% | 2025-09-30 |
| Franklin Resources Inc | $467.00 | 3.8% | 189,894 | 0 | 0% | 2025-09-30 |
| Stonepine Capital Management, Llc | $392.00 | 3.19% | 159,421 | +76,991 | +93.4% | 2025-09-30 |
| Alyeska Investment Group, L.P. | $203.00 | 1.65% | 82,484 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $146.00 | 1.19% | 59,418 | -679 | -1.13% | 2025-09-30 |
| Two Sigma Investments, Lp | $122.00 | 0.99% | 49,453 | +49,453 | New | 2025-09-30 |
| Two Sigma Advisers, Lp | $113.00 | 0.92% | 45,751 | +45,751 | New | 2025-09-30 |
| Jane Street Group, Llc | $64.00 | 0.52% | 26,182 | +26,182 | New | 2025-09-30 |
| Citadel Advisors Llc | $61.00 | 0.5% | 24,728 | +24,728 | New | 2025-09-30 |
| Geode Capital Management, Llc | $47.00 | 0.39% | 19,292 | +472 | +2.51% | 2025-09-30 |